Ignite Creation Date:
2024-05-06 @ 1:00 PM
Last Modification Date:
2024-10-26 @ 1:07 PM
Study NCT ID:
NCT03901469
Status:
TERMINATED
Last Update Posted:
2024-05-03
First Post:
2019-03-22
Brief Title:
A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer
Sponsor:
Zenith Epigenetics
Organization:
Zenith Epigenetics
Study Overview
Official Title:
A Phase 2b Study of ZEN003694 in Combination With Talazoparib in Patients With Triple-Negative Breast Cancer
Status:
TERMINATED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Parts 1 and 2 and Expansion Cohort C were completed Expansion Cohorts A and B were discontinued based on results from an interim futility analysis and not due to safety concerns
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TNBC
Brief Summary:
This is a two-part open label non-randomized Phase 2 study of ZEN003694 in combination with Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2 Part 1 is a dose escalation and Part 2 is a Simon 2-Stage design There are 3 expansion cohorts Expansion Cohort A combination treatment in post-TROP2-ADC patients Expansion Cohort B ZEN003694 monotherapy and Expansion Cohort C combination treatment in TROP2-ADC-naive patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2018-003906-26 | EUDRACT_NUMBER | None | None |